Covered recipient · General Payments record
NIRISHA KALAKADA
Allopathic & Osteopathic Physicians Internal Medicine
General Payments · PY2019–2024
$533.00
- Reported across 27 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $345.28 | 17 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Novo Nordisk AS | $240.75 | 12 |
| GlaxoSmithKline, LLC. | $27.22 | 1 |
| PFIZER INC. | $25.59 | 1 |
| Esperion Therapeutics, Inc. | $19.70 | 1 |
| Lilly USA, LLC | $16.48 | 1 |
| Amgen Inc. | $15.54 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (17)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Amgen Inc. | $15.54 | 04/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1115781209 | CMS |
| Esperion Therapeutics, Inc. | $19.70 | 06/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1129440682 | CMS |
| GlaxoSmithKline, LLC. | $27.22 | 12/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116675953 | CMS |
| Lilly USA, LLC | $16.48 | 01/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135252928 | CMS |
| Novo Nordisk Inc | $15.53 | 02/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096644097 | CMS |
| Novo Nordisk Inc | $24.75 | 02/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096916700 | CMS |
| Novo Nordisk Inc | $21.59 | 03/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097112914 | CMS |
| Novo Nordisk Inc | $12.56 | 05/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096592902 | CMS |
| Novo Nordisk Inc | $23.81 | 05/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097043801 | CMS |
| Novo Nordisk Inc | $18.98 | 07/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096577803 | CMS |
| Novo Nordisk Inc | $12.86 | 08/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096641328 | CMS |
| Novo Nordisk Inc | $9.72 | 09/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097835342 | CMS |
| Novo Nordisk Inc | $23.29 | 09/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096596916 | CMS |
| Novo Nordisk Inc | $23.01 | 10/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096715747 | CMS |
| Novo Nordisk Inc | $30.33 | 10/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096576733 | CMS |
| Novo Nordisk Inc | $24.32 | 12/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097057724 | CMS |
| PFIZER INC. | $25.59 | 06/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131647133 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2019, 2020, 2022, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.